

Meeting Minutes
Incontinence in Neurological Disease - GDG Meeting 4
Location: National Clinical Guideline Centre – Board Room
4th February, 2011

GDG		NCGC	
Allison Bardsley	AB	Gill Ritchie	GR
Alun Williams	AW	Ralph Hughes	RH
Amelia Denny	AD	Philippe Laramee	PL
Christine Anderson	CA	Richard Whittome (pm only)	RW
Clare Fowler	CF	Tamara Diaz	TD
Doreen McClug	DM	Mark Perry	MP
Judith Jesky	JJ		
Julie Vickerman	JV	NICE Observer	
Keith MacDermott	KM	Sarah Dunsdon	SD
Laura Graham	LGr		
Noreen Barker	NB	NCGC Observers	
Paul Tophill	PT	Katharina Dworzinsky	KD
Simon Harrison (Chair)	SH		
Sue Woodward	SW		
Susie Orme	SO		

1. Introduction

- 1.1. The Chair (SH) welcomed attendees to the Incontinence in Neurological Disease (IND) guideline development group (GDG) meeting 5 and apologies were heard for Sharon Swain. The GDG were introduced to Katharina Dworzinsky attending as an observer. This was the last meeting PL would be attending and RH would be taking over as the Health Economist.
- 1.2. Declarations of Interest pertaining to the day's agenda had been submitted by Clare Fowler and Laura Graham and these were noted as follows:
 - 1.2.1. Laura Graham – Personal non-pecuniary interest: Sponsorship of educational meetings by companies producing Botulinum toxin.
 - 1.2.2. Clare Fowler – Non-personal pecuniary interest: received unrestricted educational grants from Allergan, the manufacturer of Botox®, to carry out laboratory investigations of the mechanism of action Botulinum toxin A when injected into the detrusor muscle as a treatment of detrusor overactivity. The treatment is currently undergoing licensing trials, and her department is a trial centre. An invited member of Allergan advisory boards, Clare advised that she has spoken at teaching courses about the treatment. The Chair advised that CF would not participate in decision making or wording of any recommendations with respect to individual preparations of Botulinum Toxin.
- 1.3. The Minutes of GDG 3 were reviewed.
 Pending the following change the minutes of GDG 3 were agreed by the group:
 Page 1: Point 1.2 - Add declarations of interest from Simon Harrison and Paul Tophill.
- 1.4. The Chair presented an overview of the agenda.

2. Review of Clinical and Health Economic Evidence:

2.1. What is the safety and efficacy of botulinum toxin compared with a) usual care b) antimuscarinics c) augmentation cystoplasty in neurological disease?

2.1.1. Clinical Evidence

No studies were identified on Botulinum-B toxin or comparing botulinum toxin with augmentation cystoplasty. The clinical evidence was presented by the Chair in the following subsets, and reported according to manufacturer:

- Children
- Adults – Shorter term safety and efficacy
- Adults – longer term follow up data.

2.1.2. Health Economic Evidence

RH and PL presented Health Economic evidence to the GDG. Two economic analyses were included in this review.

3. Economic Report – Referral for Specialist Assessment

There were no economic evaluations for this question. Costing information related to referrals was presented to the GDG.

4. Economic Model - Monitoring

RH presented a review that included information sourced from international and national guidance on monitoring strategies. RH led discussions with the GDG to determine current practice throughout the NHS and more specific information on costing.

5. Review and agree key clinical questions

GR presented and obtained agreement from the GDG on the review protocols for questions related to: patients' experience of services, information provision and configuration of services.

6. Close

There being no further business the meeting ended at 4:00 p.m. The next GDG meeting which will be held on 11th March, 2011 from 10:30 – 16:30 will take place at the Linacre Room at the Royal College of Physicians.